Putative effects of cannabidiol in depression and synaptic plasticity

Joca, Sâmia; Silote, Gabriela Pandini; Sartim, Ariandra Guerini; Sales, Amanda J.; Guimarães, Francisco Silveira; Wegener, Gregers

doi:10.1016/b978-0-12-817933-8.00052-9

Cited by 4 publications

(9 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both in vivo and in vitro studies have shown that chronic CBD treatment promotes hippocampal neurogenesis and synaptogenesis by increasing anandamide signaling in the hippocampus, while endocannabinoid system signaling promotes neurogenesis via CB1 and CB2 receptors. These observations may represent evidence to support CBD as a potential drug to treat mood disorders [26,84].…”

Section: Cannabidiol (Cbd)-type Compoundsmentioning

confidence: 69%

“…Although it has a low affinity for these receptors, it is nevertheless interesting that CBD may favor increases in endogenous endocannabinoid levels by indirect mechanisms. However, its actions are much more varied: for example, it intervenes in modulating the activity of some neurotransmitter transporters such as dopamine, norepinephrine, adenosine, and glutamate [84,138].…”

Section: Cannabidiol (Cbd)-type Compoundsmentioning

confidence: 99%

“…It can be an agonist of transient receptors (TRPV1), of 5-HT1A receptor, and of PPARγ receptor, or it can modulate the activity of numerous ion channels and various enzymes as well as modulating G55 protein-coupled receptor (GPR55) [84].…”

Section: Cannabidiol (Cbd)-type Compoundsmentioning

confidence: 99%

“…Epidiolex, a prescription medicine that contains CBD, was the first drug approved in June 2018 by the Food and Drug Administration (FDA) [84,140,146], and in 2019, it was also approved by the European Medicines Agency (EMA), in the treatment of seizures associated with Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS), as well as seizures associated with tuberous sclerosis [26,87,147].…”

Section: Cannabidiol (Cbd)-type Compoundsmentioning

confidence: 99%

See 3 more Smart Citations

Major Phytocannabinoids and Their Related Compounds: Should We Only Search for Drugs That Act on Cannabinoid Receptors?

et al. 2021

View full text Add to dashboard Cite

The most important discoveries in pharmacology, such as certain classes of analgesics or chemotherapeutics, started from natural extracts which have been found to have effects in traditional medicine. Cannabis, traditionally used in Asia for the treatment of pain, nausea, spasms, sleep, depression, and low appetite, is still a good candidate for the development of new compounds. If initially all attention was directed to the endocannabinoid system, recent studies suggest that many of the clinically proven effects are based on an intrinsic chain of mechanisms that do not necessarily involve only cannabinoid receptors. Recent research has shown that major phytocannabinoids and their derivatives also interact with non-cannabinoid receptors such as vanilloid receptor 1, transient receptor ankyrin 1 potential, peroxisome proliferator-activated receptor-gamma or glitazone receptor, G55 protein-coupled receptor, and nuclear receptor, producing pharmacological effects in diseases such as Alzheimer’s, epilepsy, depression, neuropathic pain, cancer, and diabetes. Nonetheless, further studies are needed to elucidate the precise mechanisms of these compounds. Structure modulation of phytocannabinoids, in order to improve pharmacological effects, should not be limited to the exploration of cannabinoid receptors, and it should target other courses of action discovered through recent research.

show abstract

Section: Cannabidiol (Cbd)-type Compoundsmentioning

confidence: 69%

Section: Cannabidiol (Cbd)-type Compoundsmentioning

confidence: 99%

Section: Cannabidiol (Cbd)-type Compoundsmentioning

confidence: 99%

Section: Cannabidiol (Cbd)-type Compoundsmentioning

confidence: 99%

See 2 more Smart Citations

Major Phytocannabinoids and Their Related Compounds: Should We Only Search for Drugs That Act on Cannabinoid Receptors?

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Because of its non-psychostimulant effects, the therapeutic potential of CBD has been explored in a wide range of neuropsychiatric disorders, such as schizophrenia, epilepsy, depression, and bipolar disorder [ 27 ]. CBD was shown to reduce psychotic symptoms in schizophrenia patients and decrease anxiety in preclinical and clinical studies, and preclinical evidence suggests it to be a promising new antidepressant [ 34 ]. However, the exact molecular mechanism of the action underlying changes in these symptoms is still unknown.…”

Section: Introductionmentioning

confidence: 99%

The Cannabis-Induced Epigenetic Regulation of Genes Associated with Major Depressive Disorder

Sayed

Joca

Starnawska

2022

Genes

View full text Add to dashboard Cite

The prevalence of depression is increasing worldwide, as is the number of people suffering from treatment-resistant depression; these patients constitute 30% of those treated. Unfortunately, there have not been significant advances in the treatment of this disorder in the past few decades. Exposure to cannabis and cannabis-derived compounds impacts depression symptomatology in different ways, with evidence indicating that cannabidiol has antidepressant effects; there have been mixed results with medical cannabis. Even though the exact molecular mechanisms of the action underlying changes in depression symptomatology upon exposure to cannabis and cannabis-derived compounds are still unknown, there is strong evidence that these agents have a widespread impact on epigenetic regulation. We hypothesized that exposure to cannabis or cannabis-derived compounds changes the DNA methylation levels of genes associated with depression. To test this hypothesis, we first performed a literature search to identify genes that are differentially methylated upon exposure to cannabis and cannabis-derived compounds, as reported in methylome-wide association studies. We next checked whether genes residing in loci associated with depression, as identified in the largest currently available genome-wide association study of depression, were reported to be epigenetically regulated by cannabis or cannabis-related compounds. Multiple genes residing in loci associated with depression were found to be epigenetically regulated by exposure to cannabis or cannabis-derived compounds. This epigenomic regulation of depression-associated genes by cannabis or cannabis-derived compounds was reported across diverse organisms, tissues, and developmental stages and occurred in genes crucial for neuronal development, functioning, survival, and synapse functioning, as well as in genes previously implicated in other mental disorders.

show abstract